ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • Register
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 1335

Long–Term Safety and Efficacy of Adalimumab in Patients with Non-Infectious Intermediate, Posterior, or Panuveitis in an Ongoing Open-Label Study

Eric B. Suhler1, Glenn J. Jaffe2, Quan Dong Nguyen3, Antoine P. Brezin4, Manfred Zierhut5, Albert Vitale6, Mirjam van Velthoven7, Alfredo Adan8, Lyndell Lim9, Michal Kramer10, Ariel Schlaen11, Eric Fortin12, Cristina Muccioli13, Hiroshi Goto14, Toshikatsu Kaburaki15, Anne Camez16, Alexandra P. Song17, Martina Kron16, Samir Tari17 and Andrew D. Dick18, 1Oregon Health & Science University, Casey Eye Institute, and VA Portland Health Care System, Portland, OR, 2Duke University, Durham, NC, 3Truhlsen Eye Institute, University of Nebraska Medical Center, Omaha, NE, 4Université Paris Descartes, Hôpital Cochin, Paris, France, 5Center of Ophthalmology, University of Tuebingen, Tuebingen, Germany, 6University of Utah, Salt Lake City, UT, 7Rotterdam Eye Hospital, Rotterdam, Netherlands, 8Ophthalmology, Hospital Clinic de Barcelona,, Barcelona, Spain, 9Centre for Eye Research Australia, Royal Victorian Eye and Ear Hospital, East Melbourne, Australia, 10Rabin Medical Center, Petach Tikva, Tel Aviv University, Tel Aviv, Israel, 11Austral University, Buenos Aires, Argentina, 12University of Montreal, Montreal, QC, Canada, 13Federal University of São Paulo, São Paulo, Brazil, 14Tokyo Medical University, Tokyo, Japan, 15Ophthalmology, The University of Tokyo School of Medicine, Bunkyo-ku, Japan, 16Abbvie Deutschland GmbH & Co KG, Ludwigshafen, Germany, 17AbbVie Inc., North Chicago, IL, 18University of Bristol, Bristol Eye Hospital; National Institute for Health Research (NIHR) Biomedical Research Centre at Moorfields Eye Hospital and University College London, Institute of Ophthalmology, London, United Kingdom

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: Adalimumab and uveitis

  • Tweet
  • Email
  • Print
Save to PDF
Session Information

Date: Monday, November 14, 2016

Session Title: Miscellaneous Rheumatic and Inflammatory Diseases - Poster II

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose:  To evaluate the long-term safety and efficacy of adalimumab (Humira®) in patients with non-infectious intermediate, posterior, or panuveitis (NIPPU) in an open-label clinical trial extension, VISUAL-III.

Methods:  Adults who met treatment failure or study completion criteria in VISUAL-I/VISUAL-II and opted to enroll in VISUAL-III received adalimumab 40-mg every other week. Corticosteroids and/or immunosuppressive therapy were permitted as needed. Patients that discontinued VISUAL-I/VISUAL-II due to treatment failure had active disease at VISUAL-III entry. Efficacy endpoints included new inflammatory lesions, anterior chamber (AC) cell, and vitreous haze (VH) grades from study entry (week-0) through week-54 (inactive uveitis) and week-78 (active uveitis). Corticosteroid daily dose was measured over time. Adverse event rates were reported from first adalimumab dose in VISUAL-I/II/III until the data cutoff of 31-August-2015.

Results:  Intent-to-treat analyses included 243 (active) and 128 (inactive) uveitis patients at study entry. At week-54, no new inflammatory lesions relative to baseline, AC cell and VH grades of ≤0.5+ were observed in 98.5%, 98.5% and 92.6% of inactive uveitis patients, respectively. At week-78, no new inflammatory lesions relative to week-8, AC cell and VH grades of ≤0.5+ were observed in 96.3%, 91.0% and 87.8% of active uveitis patients, respectively. Mean systemic corticosteroid daily dose decreased from 12.7 to 3.68 prednisone equivalents by year 1 for patients with active uveitis and remained stable from 1.48 to 1.21 prednisone equivalents for inactive patients. Adverse events rates (577 AE/100PY and 19.6 SAE/100PY) were comparable to the VISUAL-I and VISUAL-II trials.

Conclusion:  Long-term adalimumab treatment reduced ocular inflammation and corticosteroid burden in NIPPU patients and demonstrated a safety profile consistent with other indications and previous VISUAL studies.


Disclosure: E. B. Suhler, AbbVie, 9,AbbVie, Mallinckrodt, Santen, and XOMA, 5,AbbVie, Bristol Myers Squibb, Clearside, EyeGate, and Genentech, 2,Research to Prevent Blindness and the Department of Veterans Affairs, 9; G. J. Jaffe, AbbVie, 5; Q. D. Nguyen, AbbVie, Santen, XOMA, Bausch & Lomb, 9; A. P. Brezin, AbbVie, 5,AbbVie, 9; M. Zierhut, AbbVie and Santen, 9; A. Vitale, ACIONT, 5; M. van Velthoven, AbbVie Netherlands, Novartis Netherlands and Bayer Netherlands, 8,Allergan Europe, 9; A. Adan, AbbVie, Santen and Allergan, 9; L. Lim, AbbVie, Bayer and Allergan, 5,AbbVie, Bayer and Allergan, 9; M. Kramer, AbbVie, 5; A. Schlaen, None; E. Fortin, AbbVie, Alcon and Allergan, 5,AbbVie, Alcon and Allergan, 9; C. Muccioli, AbbVie, 5; H. Goto, AbbVie, 9; T. Kaburaki, None; A. Camez, Abbvie, 1,AbbVie, 3; A. P. Song, AbbVie, 1,AbbVie, 3; M. Kron, AbbVie, 1,AbbVie, 3; S. Tari, AbbVie, 1,AbbVie, 3; A. D. Dick, AbbVie, 9.

To cite this abstract in AMA style:

Suhler EB, Jaffe GJ, Nguyen QD, Brezin AP, Zierhut M, Vitale A, van Velthoven M, Adan A, Lim L, Kramer M, Schlaen A, Fortin E, Muccioli C, Goto H, Kaburaki T, Camez A, Song AP, Kron M, Tari S, Dick AD. Long–Term Safety and Efficacy of Adalimumab in Patients with Non-Infectious Intermediate, Posterior, or Panuveitis in an Ongoing Open-Label Study [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/long-term-safety-and-efficacy-of-adalimumab-in-patients-with-non-infectious-intermediate-posterior-or-panuveitis-in-an-ongoing-open-label-study/. Accessed January 20, 2021.
  • Tweet
  • Email
  • Print
Save to PDF

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/long-term-safety-and-efficacy-of-adalimumab-in-patients-with-non-infectious-intermediate-posterior-or-panuveitis-in-an-ongoing-open-label-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Convergence: Where Rheumatology Meets. All Virtual. November 5-9.

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2021 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.